Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT03004326RecruitingPrimary

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT07268521Phase 2Not Yet RecruitingPrimary

A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab

Showing all 2 trials

Research Network

Activity Timeline